

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, Alexandria, VA 22313-1450 on the date shown below:

INFORMATION DISCLOSURE STATEMENT  
Patent Application  
Docket No. ARYX-105X2C2  
Serial No. 10/822,129

*SPW*

May 10, 2004  
David Saliwanchik  
David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : *(not yet known)*  
Applicant : Pascal Druzgala, Xiaoming Zhang, Jurg R. Pfister  
Serial No. : 10/822,129  
Filed : April 8, 2004  
Conf. No. : *(not yet known)*  
For : Materials and Methods for Treating Coagulation Disorders

Mail Stop Amendment  
Commissioner for Patents  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 AND 1.98


Sir:

In accordance with 37 C.F.R. § 1.56, the references on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41<sup>st</sup> Street, Suite A-1  
Gainesville, FL 32606-6669

DRS/ue

Attachments: Form PTO/SB/08

References listed thereon



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/822,129
		Filing Date	April 4, 2004
		First Named Inventor	Pascal Druzgala
		Group Art Unit	(not yet assigned)
		Examiner Name	(not yet assigned)
		Attorney Docket Number	ARYX-105X2C2

Sheet	2	of	2
-------	---	----	---

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	SCHMITT, J. <i>et al.</i> "Sur un nouvel et puissant anticoagulant de sythese," <i>Chemie Therapeutique</i> (1966), Volume 1, pages 301-304. (In French, translation also included).	
	R2	SVETLIK, JAN <i>et al.</i> "Expedient Synthesis of 3-Arylpropionic Acid Derivatives," <i>Synthetic Communications</i> (1993), Volume 23, number 5, pages 631-640.	
	R3	THAISRIVONGS, SUVIT <i>et al.</i> "Structure-based Design of Novel HIV Inhibitors: Carboxamide-Containing 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Potent Nonpeptidic Inhibitors," <i>J. Med. Chem.</i> (1995), Volume 38, pages 3624-3637.	
	R4	ZHAO, H. <i>et al.</i> "Coumarin-based inhibitors of HIV Integrase," <i>J. Med. Chem.</i> (1997), Volume 40, pages 242-249.	
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (08-00)



Please type a (+) sign (+) inside this box → ☒

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/822,129
				<b>Filing Date</b>	April 4, 2004
				<b>First Named Inventor</b>	Pascal Druzgala
				<b>Group Art Unit</b>	(not yet assigned)
				<b>Examiner Name</b>	(not yet assigned)
<b>Sheet</b>	1	of	2	<b>Attorney Docket Number</b>	ARYX-105X2C2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	U1	US-3,325,515		Schmitt <i>et al.</i>	05-13-1967	All
	U2	US-4,748,185		Entwistle <i>et al.</i>	05-31-1988	All
	U3	US-5,856,525		Li <i>et al.</i>	01-05-1999	All
	U4	US-5,686,486		Tomich <i>et al.</i>	11-11-1997	All
	U5					
	U6					
	U7					
	U8					
	U9					
	U10					
	U11					
	U12					
	U13					
	U14					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	F1	GB	1,032,253		Fo We Forschungs Und Verwertungs Anstalt	06-08-1966	All	
	F2	GB	1,024,383		Fo We Forschungs Und Verwertungs Anstalt	3-30-1966	All	
	F3	FR	2,765,579	A1	Lipha Lyonnaise Industrielle Pharmaceutique Societe Anonyme	01-08-1999	All	
	F4							
	F5							

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.